$0.335
+0.008 (+2.29%)收盤時
ACTU 同業比較
In the context of the broader market, ACTU competes directly with industry leaders such as CNTX and QNRX. With a market capitalization of $8.03M, it holds a significant position in the sector. When comparing efficiency, ACTU's gross margin of N/A stands against CNTX's N/A and QNRX's N/A. Such benchmarking helps identify whether Actuate Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Actuate Therapeutics Inc 財務表現
Actuate Therapeutics has shown a consistent negative net income, with the latest reported net income of -5,625,749 USD for Q1 2026. The company's debt-to-equity ratio is high at 40.94%, indicating significant leverage.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
-17.80%
-4.91M
Operating Profit
FY2026Q2
YoY:
-18.20%
-4.87M
Net Income after Tax
FY2026Q2
YoY:
-33.33%
-0.20
EPS - Diluted
FY2026Q2
YoY:
+5.54%
-4.41M
Free Cash Flow
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。